KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) EBT (2017 - 2025)

Twist Bioscience (TWST) has disclosed EBT for 6 consecutive years, with -$46.5 million as the latest value for Q3 2023.

  • On a quarterly basis, EBT rose 8.57% to -$46.5 million in Q3 2023 year-over-year; TTM through Sep 2023 was -$203.5 million, a 10.87% increase, with the full-year FY2025 number at -$77.0 million, up 63.03% from a year prior.
  • EBT was -$46.5 million for Q3 2023 at Twist Bioscience, up from -$56.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$24.1 million in Q3 2020 to a low of -$60.8 million in Q1 2022.
  • A 5-year average of -$42.7 million and a median of -$41.7 million in 2022 define the central range for EBT.
  • Peak YoY movement for EBT: tumbled 146.07% in 2019, then surged 40.91% in 2020.
  • Twist Bioscience's EBT stood at -$55.6 million in 2019, then skyrocketed by 40.91% to -$32.9 million in 2020, then tumbled by 70.35% to -$56.0 million in 2021, then rose by 25.41% to -$41.7 million in 2022, then dropped by 11.3% to -$46.5 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's EBT are -$46.5 million (Q3 2023), -$56.8 million (Q2 2023), and -$58.5 million (Q1 2023).